Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 9/20 | 0.90 |
| ▸ | MEN1 | O00255 | 8/20 | 0.90 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.76 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.76 |
| ▸ | MAPT | P10636 | 7/20 | 0.69 |
| ▸ | LMNA | P02545 | 4/20 | 0.68 |
| ▸ | GAA | P10253 | 2/20 | 0.68 |
| ▸ | HTT | P42858 | 2/20 | 0.68 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.66 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.66 |
| ▸ | POLB | P06746 | 1/20 | 0.66 |
| ▸ | XBP1 | P17861 | 1/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.66 |
| ▸ | TSHR | P16473 | 1/20 | 0.66 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.66 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.65 |
| ▸ | HPGD | P15428 | 1/20 | 0.65 |
| ▸ | NPC1 | O15118 | 1/20 | 0.62 |
| ▸ | RAB9A | P51151 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL359543 | 0.89 | MEN1 (0.72) | KMT2AMEN1ALDH1A1KDM4EMAPT | |
| SCHEMBL3604124 | 0.87 | KMT2A (0.74) | KMT2AMEN1ALDH1A1KDM4EMAPT | |
| SCHEMBL8303947 | 0.87 | ALDH1A1 (0.71) | KMT2AMEN1ALDH1A1KDM4EMAPT | |
| SCHEMBL1454119 | 0.86 | KMT2A (0.73) | KMT2AMEN1ALDH1A1KDM4EMAPT | |
| SCHEMBL1455196 | 0.86 | KMT2A (0.73) | KMT2AMEN1ALDH1A1KDM4EMAPT | |
| SCHEMBL5390788 | 0.86 | KMT2A (0.69) | KMT2AMEN1ALDH1A1KDM4EMAPT | |
| SCHEMBL1455800 | 0.86 | KMT2A (0.73) | KMT2AMEN1ALDH1A1KDM4EMAPT | |
| SCHEMBL27942800 | 0.86 | KMT2A (0.72) | KMT2AMEN1ALDH1A1KDM4EMAPT | |
| SCHEMBL9237760 | 0.86 | MEN1 (0.72) | KMT2AMEN1ALDH1A1KDM4EMAPT | |
| SCHEMBL1455478 | 0.85 | MEN1 (0.68) | KMT2AMEN1ALDH1A1KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230225991-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF ACUTE INTERMITTENT PORPHYRIA | VESTLANDETS INNOVASJONSSELSKAP AS (NO) | 2023-07-20 | — | — | US | disclosed |
| EP-4061347-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF ACUTE INTERMITTENT PORPHYRIA | Vestlandets Innovasjonsselskap AS (NO) | 2022-09-28 | — | — | EP | disclosed |
| WO-2021099803-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF ACUTE INTERMITTENT PORPHYRIA | VESTLANDETS INNOVASJONSSELSKAP AS (NO) | 2021-05-27 | — | — | WO | disclosed |
| US-8338605-B2 | Anti-viral compounds | ABBOTT LABORATORIES (US) | 2012-12-25 | — | — | US | disclosed |
| US-8338605-B2 | Anti-viral compounds | ABBOTT LABORATORIES (US) | 2012-12-25 | — | — | US | disclosed |
| US-8236950-B2 | Anti-viral compounds | ABBOTT LABORATORIES (US) | 2012-08-07 | — | — | US | disclosed |
| US-8236950-B2 | Anti-viral compounds | ABBOTT LABORATORIES (US) | 2012-08-07 | — | — | US | disclosed |
| EP-1979348-B1 | ANTI-VIRAL COMPOUNDS | ABBOTT LAB (US) | 2012-01-18 | — | — | EP | disclosed |
| US-20110160233-A1 | ANTI-VIRAL COMPOUNDS | ABBOTT LABORATORIES (US) | 2011-06-30 | — | — | US | disclosed |
| US-20110160233-A1 | ANTI-VIRAL COMPOUNDS | ABBOTT LABORATORIES (US) | 2011-06-30 | — | — | US | disclosed |
| US-7763731-B2 | Anti-viral compounds | ABBOTT LABORATORIES (US) | 2010-07-27 | — | — | US | disclosed |
| EP-2094276-A2 | ANTI-VIRAL COMPOUNDS | Abbott Laboratories (US) | 2009-09-02 | — | — | EP | disclosed |
| CN-101384591-A | Antiviral compounds | ABBOTT LAB (US) | 2009-03-11 | — | — | CN | disclosed |
| WO-2008133753-A2 | ANTI-VIRAL COMPOUNDS | ABBOTT LABORATORIES (US) | 2008-11-06 | — | — | WO | disclosed |
| EP-1979348-A2 | ANTI-VIRAL COMPOUNDS | Abbott Laboratories (US) | 2008-10-15 | — | — | EP | disclosed |
| US-20070232645-A1 | ANTI-VIRAL COMPOUNDS | ABBVIE INC. | 2007-10-04 | — | — | US | disclosed |
| US-20070232645-A1 | ANTI-VIRAL COMPOUNDS | ABBVIE INC. | 2007-10-04 | — | — | US | disclosed |
| US-20070232627-A1 | ANTI-VIRAL COMPOUNDS | ABBVIE INC. | 2007-10-04 | — | — | US | disclosed |
| US-20070232627-A1 | ANTI-VIRAL COMPOUNDS | ABBVIE INC. | 2007-10-04 | — | — | US | disclosed |
| WO-2007076034-A2 | ANTI-VIRAL COMPOUNDS | ABBOTT LABORATORIES (US) | 2007-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160233-A1 | ANTI-VIRAL COMPOUNDS | HAVCR2, MAVS, EIF2AK2 | KMT2A 3566/4885MEN1 4571/4885ALDH1A1 2723/4885 |
| US-20070232645-A1 | ANTI-VIRAL COMPOUNDS | HAVCR2, MAVS, EIF2AK2 | KMT2A 3566/4885MEN1 4571/4885ALDH1A1 2723/4885 |
| US-20070232627-A1 | ANTI-VIRAL COMPOUNDS | HAVCR2, MAVS, EIF2AK2 | KMT2A 3566/4885MEN1 4571/4885ALDH1A1 2723/4885 |
| US-20230225991-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF ACUTE INTERMITTENT PORPHYRIA | HMBS, POR, CYP2A13 | KMT2A 2673/4885MEN1 3892/4885ALDH1A1 968/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.